Fibroblast Growth Factor-2 Induces Recovery of Pulmonary Blood Flow in Canine Emphysema Models

• Published in: Chest Vol. 128; no. 2; pp. 920 - 926
• Main Authors: Morino, Shigeyuki, Nakamura, Tatsuo, Toba, Toshinari, Takahashi, Mitsuru, Kushibiki, Toshihiro, Tabata, Yasuhiko, Shimizu, Yasuhiko
• Format: Journal Article
• Language: English
• Published: Northbrook, IL Elsevier Inc 01.08.2005; American College of Chest Physicians
• Subjects: Angiogenesis; Animals; Biological and medical sciences; Cardiology. Vascular system; COPD; Disease Models, Animal; Dogs; Emphysema; Female; fibroblast growth factor; Fibroblast Growth Factor 2 - pharmacology; Fibroblast Growth Factor 2 - physiology; Fibroblast Growth Factor 2 - therapeutic use; Fibroblasts; General anesthesia; Growth factors; Laboratory animals; Medical sciences; Mortality; Oxygen saturation; Pneumology; Pulmonary Circulation - drug effects; Pulmonary Circulation - physiology; Pulmonary Emphysema - drug therapy; Pulmonary Emphysema - physiopathology; Rats; Rats, Wistar; regeneration; Thoracic surgery; Ventilation; Japan; Lm; fibroblast growth factor; FGF; FGF + group; regeneration; angiogenesis; P/V; FGF − group; LVRS; COPD; emphysema; Fissipedia; Lung disease; Fibroblast growth factor; Carnivora; Respiratory disease; Cardiovascular disease; Recovery; emphyscma; Blood flow; Angiogenesis; Regeneration; Vertebrata; Chronic; Mammalia; Animal; Models; Pulmonary emphysema; Hemodynamics; Neovascularization; Dog
• ISSN: 0012-3692; 1931-3543
• DOI: 10.1378/chest.128.2.920

Fibroblast growth factor (FGF)-2 is one of the most powerful angiogenic growth factors to be evaluated as an agent for the promotion of angiogenesis. The aim of this study is to investigate whether intratracheal administration of controlled-release FGF-2 microspheres restores pulmonary function in beagle dogs with emphysema Randomized, controlled, experimental animal study Eighteen Wister rats and 15 adult beagle dogs In the rat study, we compared the time profiles of the radioactivity remaining after intratracheal injection of125I-labeled FGF-2, either incorporated with the controlled-release microspheres or as an aqueous solution. In the dog study, elastase-induced emphysema models were developed in 10 animals, classified into the following three groups: control group (n = 5), emphysema model with empty microspheres-treated group (FGF − group, n = 5), and emphysema model with FGF-2 containing microspheres-treated group (FGF + group, n = 5) In the rat study, controlled-release microspheres maintained higher whole-lung FGF-2 concentrations after intratracheal administration. In the dog study, Pao2in the FGF + group was significantly higher than in the FGF − group after treatment. Pulmonary perfusion dynamic MRI revealed significant improvement in the signal intensity of damaged lung with the FGF + group. Linear intercept of the FGF + group was significantly reduced than the FGF − group Results indicate that intratracheal administration of FGF-2 induced an increase in pulmonary blood flow in the damaged lung and led to recovery of pulmonary function. The controlled-release microsphere system increased the effectiveness of FGF-2